Stock Events

Stock Events

Avenue Therapeutics 

$0.5300
28
-$0.04-7.02% Thursday 15:51

Statistics

Day High
0.57
Day Low
0.4949
52W High
0.9699
52W Low
0.15
Volume
2,750
Avg. Volume
3,517
Mkt Cap
1.75M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13NovExpected
Q3 2024
Q4 2024
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.92
-1.35
-0.78
-0.21
Expected EPS
N/A
Actual EPS
N/A

Financials

-207.19%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
1.4MRevenue
-2.91MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ATXI. It's not an investment recommendation.
Apple
5
AAPL
Vanguard S&P 500
4
VOO
Microsoft
3
MSFT
Tesla
3
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.46B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, competing in the pain management market where Avenue Therapeutics also operates.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical segment, competes in developing treatments for pain management, directly competing with Avenue's focus.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie competes in the chronic pain treatment market with its portfolio of pain management drugs, overlapping with Avenue Therapeutics' interests.
Pfizer
PFE
Mkt Cap159.36B
Pfizer offers a range of products for pain management, making it a competitor in the same therapeutic area as Avenue Therapeutics.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. has a diverse portfolio that includes pain management solutions, positioning it as a competitor.
Novartis
NVS
Mkt Cap292.35B
Novartis AG, with its broad range of medicines, including those for pain management, competes in the same space as Avenue Therapeutics.
Pacira BioSciences
PCRX
Mkt Cap1.03B
Pacira BioSciences, Inc. is known for its non-opioid pain management and surgical care products, competing in the same market as Avenue Therapeutics.

About

Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the management of severe pain experienced by patients after surgery. Established in 2015, the company's operations are based in New York, New York.
Show more...
CEO
Alexandra MacLean
Employees
1
Country
United States
ISIN
US05360L4032
WKN
000A40BWJ

Listings

MU
DE
49Y0.MU
OTC Link
US
ATXI

0 Comments

Share your thoughts

FAQ

What is Avenue Therapeutics stock price today?▼
The current price of ATXI is $0.53 USD — it has decreased by -7.02% in the past 24 hours. Watch Avenue Therapeutics stock price performance more closely on the chart.
What is Avenue Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Avenue Therapeutics stocks are traded under the ticker ATXI.
Is Avenue Therapeutics stock price growing?▼
ATXI stock has risen by +17.26% compared to the previous week, the month change is a +76.37% rise, over the last year Avenue Therapeutics has showed a -18.46% decrease.
What is Avenue Therapeutics market cap?▼
Today Avenue Therapeutics has the market capitalization of 1.75M
When is the next Avenue Therapeutics earnings date?▼
Avenue Therapeutics is going to release the next earnings report on November 13, 2026.
What is Avenue Therapeutics revenue for the last year?▼
Avenue Therapeutics revenue for the last year amounts to 1.4M USD.
What is Avenue Therapeutics net income for the last year?▼
ATXI net income for the last year is -2.91M USD.
How many employees does Avenue Therapeutics have?▼
As of September 04, 2026, the company has 1 employees.
In which sector is Avenue Therapeutics located?▼
Avenue Therapeutics operates in the Health & Wellness sector.
When did Avenue Therapeutics complete a stock split?▼
The last stock split for Avenue Therapeutics was on April 26, 2024 with a ratio of 1:75.
Where is Avenue Therapeutics headquartered?▼
Avenue Therapeutics is headquartered in Bay Harbor Islands, United States.